<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63832">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02001337</url>
  </required_header>
  <id_info>
    <org_study_id>10-006868</org_study_id>
    <nct_id>NCT02001337</nct_id>
  </id_info>
  <brief_title>Examination of the Pancreas in New-onset Diabetes</brief_title>
  <acronym>EXPAND</acronym>
  <official_title>Examination of the Pancreas in New-onset Diabetes (EXPAND Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to create a prospective cohort of subjects with increased
      probability of being diagnosed with pancreatic cancer and then screen this cohort for
      pancreatic cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compared to the general population, subjects &gt;50 years of age with new-onset diabetes (DM)
      are 8-times more likely to have pancreatic cancer (PaC). The likelihood of PaC in new-onset
      DM is further increased in those who have weight loss or elevated CA19-9. In this study
      patients with newly diagnosed diabetes will be prospectively identified. Those with weight
      loss and/or elevated pancreatic cancer marker (CA 19-9) will undergo pancreatic imaging. All
      subjects will be followed up to 24 months.   If successful in identifying surgically
      removable PaC, this study will fundamentally change our practice and will be a major
      breakthrough in PaC treament and research.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>To create a prospective cohort of subjects with increased probability of being diagnosed with pancreatic cancer and identify pancreatic cancer in this cohort.</measure>
    <time_frame>Follow subjects for 2 years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will prospectively identify patients with newly diagnosed diabetes and perform pancreatic imaging to identify pancreatic cancer</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical chart review</intervention_name>
    <description>baseline, quarterly follow-up for 24 months</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>survey administration</intervention_name>
    <description>baseline</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Specimen collection</intervention_name>
    <description>baseline</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      20 ml of whole blood.  5ml urine sample for pregancy testing (if necessary).  Stool and
      saliva samples may be collected.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Suspected or definite new-onset diabetes
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patient Characteristics:

        --Suspected or definite new-onset diabetes based on recent blood sugar and hemoglobin A1c
        values

          -  No acute illness or steroid therapy

          -  No prior pancreas surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suresh Chari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brenda Mueller</last_name>
    <phone>1-800-914-7962</phone>
    <email>pancreas@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suresh T. Chari, MD</last_name>
    </contact>
    <investigator>
      <last_name>Suresh T. Chari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>November 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Suresh T. Chari, M.D.</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>new-onset diabetic</keyword>
  <keyword>diabetes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancrelipase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
